Use of the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) in the Diagnosis of Pleural Effusion

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified May 2005 by National Taiwan University Hospital.
Recruitment status was: Recruiting

Sponsor:

Information provided by:

National Taiwan University Hospital

ClinicalTrials.gov Identifier:

NCT00166894

First received: September 12, 2005

Last updated: November 23, 2005

Last verified: May 2005

History of Changes

Purpose

The aim of this trial is to evaluate the level of TREM-1 in different kinds of pleural effusion.

Condition
Pleural Effusion


Study Type:	Observational
Study Design:	Allocation: Random Sample Observational Model: Natural History Time Perspective: Cross-Sectional Time Perspective: Prospective
Official Title:	Evaluation of the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) as a Diagnostic Tool for Patients With Pleural Effusion

Further study details as provided by National Taiwan University Hospital:


Estimated Enrollment:	100
Study Start Date:	May 2005

Detailed Description:

The triggering receptor expressed on myeloid cells-1 (TREM-1) is a member of the immunoglobulin superfamily, and its expression is upregulated on phagocytic cells in the presence of bacteria or fungi. Several experiments by Bouchon and colleagues showed that TREM-1 mediates the acute inflammatory response to microbial products. Human tissues infected with bacteria are infiltrated with neutrophils and macrophages that express high levels of TREM-1. Conversely, TREM-1 is only weakly expressed in samples from patients with noninfectious inflammatory disorders. In addition, TREM-1 is shed from the membrane of activated phagocytes and can be found in a soluble form in body fluids. The presence of a soluble form of TREM-1 in samples of bronchoalveolar lavage fluid from mechanically ventilated patients has been shown to be a good indicator of infectious pneumonia.

Eligibility


Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Clinical diagnosis of pleural effusion
Pleural effusion proved by chest sonography

Exclusion Criteria:

Conditions for which thoracentesis are contraindicated
Pregnancy

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00166894

Contacts


Contact: Pan-Chyr Yang, MD, PhD	886-2-2356-2867	pcyang@ha.mc.ntu.edu.tw

Locations


Taiwan
National Taiwan University Hospital	Recruiting
Taipei, Taiwan
Contact: Pan-Chyr Yang, MD, PhD 886-2-2356-2867 pcyang@ha.mc.ntu.edu.tw
Principal Investigator: Pan-Chyr Yang, MD, PhD

Sponsors and Collaborators

National Taiwan University Hospital

Investigators


Principal Investigator:	Pan-Chyr Yang, MD, PhD	Department of International Medicine, National Taiwan University Hospital

More Information


ClinicalTrials.gov Identifier:	NCT00166894 History of Changes
Other Study ID Numbers:	9461700516
Study First Received:	September 12, 2005
Last Updated:	November 23, 2005

Keywords provided by National Taiwan University Hospital:


pleural effusion TREM-1

Additional relevant MeSH terms:


Pleural Effusion Pleural Diseases Respiratory Tract Diseases

ClinicalTrials.gov processed this record on June 23, 2017

To Top